Previous treatment by Tamoxifen unless in adjuvant and terminated more than a year before metastatic relapse
Patient with a tumor surexpressing HER2 that should be treated by trastuzumab
Patient that need an immediate local antalgic radiotherapy
Thrombo-embolism disease
serious concomitant pathology or uncontrolled that is susceptible to compromise the participation in the study
history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin) and cancers cured for at least for 5 years
patient with an history of significant cardiovascular impairment (congestive heart failure\> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia)
patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study
patient with a known allergy to one or several of the study compounds
patients who may not be regularly available due to geographical, social or family reasons
history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product
deficiencies of the upper intestinal tract, malabsorption syndrome
patient who is pregnant, breast-feeding or using inadequate contraception
Treatment with experimental drugs (mTor inhibitor or tyrosin kinase inhibitor)
Patient treated with molecules that interfer with isoenzyme CYP3A
Clareo Health | Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
